Related Experiment Video
Updated: Nov 10, 2025

Author Spotlight: A Comprehensive Protocol for Acinetobacter Biofilm Quantification, Assessment, and Visualization
Published on: August 4, 2023
Prevalence of multidrug-resistant Acinetobacter baumannii in a critical care setting: A tertiary teaching hospital
Thabit Alotaibi1, Abdulrhman Abuhaimed1, Mohammed Alshahrani1
1Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia.
Background:
The management of Acinetobacter baumannii infection is considered a challenge especially in an intensive care setting. The resistance rate makes it difficult to manage and is believed to lead to higher mortality. We aim to investigate the prevalence of Acinetobacter baumannii and explore how different antibiotic regimens could impact patient outcomes as there are no available published data to reflect our population in our region.
Methods:
We conducted a retrospective review of all infected adult patients admitted to the intensive care unit at King Fahad University Hospital with a confirmed laboratory diagnosis of Acinetobacter baumannii from 1 January 2013 until 31 December 2017. Positive cultures were obtained from the microbiology department and those meeting the inclusive criteria were selected. Variables were analyzed using descriptive analysis and cross-tabulation. Results were further reviewed and audited by blinded co-authors.
Results:
A comprehensive review of data identified 198 patients with Acinetobacter baumannii. The prevalence of Acinetobacter baumannii is 3.37%, and the overall mortality rate is 40.81%. Our sample consisted mainly of male patients, that is, 68.7%, with a mean age of 49 years, and the mean age of female patients was 56 years. The mean age of survivors was less than that of non-survivors, that is, 44.95 years of age. We observed that prior antibiotic use was higher in non-survivors compared to survivors. From the review of treatment provided for patients infected with Acinetobacter baumannii, 65 were treated with colistin alone, 18 were treated with carbapenems, and 22 were treated with a combination of both carbapenems and colistin. The mean length of stay of Acinetobacter baumannii-infected patients was 20.25 days. We found that the survival rates among patients who received carbapenems were higher compared to those who received colistin.Conclusion:: We believe that multidrug-resistant Acinetobacter baumannii is prevalent and associated with a higher mortality rate and represents a challenging case for every intensive care unit physician. Further prospective studies are needed.
Insights
Multidrug-resistant Acinetobacter baumannii infections are common in ICUs, leading to high mortality. Carbapenem treatment showed higher survival rates compared to colistin for Acinetobacter baumannii infections.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Microbiology
Background:
- Acinetobacter baumannii infections pose significant challenges in intensive care units (ICUs) due to high resistance rates.
- These infections are associated with increased mortality, necessitating further investigation into effective management strategies.
Purpose of the Study:
- To determine the prevalence of Acinetobacter baumannii in a specific patient population.
- To explore the impact of different antibiotic regimens on patient outcomes in Acinetobacter baumannii infections.
Main Methods:
- A retrospective review was conducted on adult patients diagnosed with Acinetobacter baumannii in the ICU from 2013 to 2017.
- Data from positive cultures were analyzed using descriptive statistics and cross-tabulation.
Main Results:
- The study identified 198 patients with Acinetobacter baumannii, showing a prevalence of 3.37% and an overall mortality rate of 40.81%.
- Patients treated with carbapenems demonstrated higher survival rates compared to those treated with colistin. Prior antibiotic use was more common in non-survivors.
Conclusions:
- Multidrug-resistant Acinetobacter baumannii is prevalent and linked to significant mortality in ICUs.
- Further prospective studies are required to validate findings and guide treatment protocols for Acinetobacter baumannii infections.
More Related Videos
05:06Author Spotlight: Advancing Antibiotic Resistance Research Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System
Published on: January 5, 2024
07:59Rapid and Specific Detection of Acinetobacter baumannii Infections Using a Recombinase Polymerase Amplification/Cas12a-based System
Published on: April 25, 2025
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Development of Antibiotic Resistance
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...